immatics seals €34m financing for development of renal cancer vaccine16 October 2013 Tuebingen-based immatics biotechnologies has closed a €34 million Series D financing round to fund development of its lead multi-peptide cancer vaccine, IMA901. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive the first €12 million tranche of funding immediately. The company says the new funds will enable it to conclude the development of the vaccine, including completing all of the activities necessary to prepare for regulatory filings in the US and Europe. IMA901 comprises 10 different tumour-associated peptides (TUMAPs) that are found to be highly over-expressed in the majority of patients suffering from renal cell carcinoma (RCC). It is in a pivotal phase 3 trial and has orphan drug designation in the US and Europe for the treatment of RCC in HLA-A*02 positive patients. Interim overall survival results are expected in 2014, with final data in 2015. The trial showed that patients who produced an immune response to two or more of the TUMAPs contained in IMA901 had a significantly longer survival, as published in Nature Medicine in 2012.[1] Reference 1. Walter S, Weinschenk T et al. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, published online: 29 July 2012. About IMA901 IMA901 is a rationally designed cancer vaccine comprising 10 different tumour-associated peptides (TUMAPs) that are found to be highly over-expressed in the majority of patients suffering from renal cell carcinoma (RCC). IMA901 is a peptide-based vaccine with a stable, off-the-shelf formulation and robust and easily scalable manufacturing.
|
|||